Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;66(6):530-42.
doi: 10.1136/jclinpath-2012-201361. Epub 2013 Feb 22.

Therapeutic targets in triple negative breast cancer

Sandra A O'Toole  1 , Jane M Beith, Ewan K A Millar, Richard West, Anna McLean, Aurelie Cazet, Alexander Swarbrick, Samantha R Oakes
Affiliations
Review

Therapeutic targets in triple negative breast cancer

Sandra A O'Toole et al. J Clin Pathol. 2013 Jun.

Abstract

Outcomes have improved significantly for many women diagnosed with breast cancer. For the heterogeneous group of tumours lacking expression of the oestrogen, progesterone and HER2 receptors, 'triple negative' breast cancers (TNBC), the prognosis overall has remained quite poor. When TNBC recurs, there is often little response to chemotherapy, and there are a few treatment options in this setting. Thus, there is an urgent clinical need to identify new therapeutic targets in order to improve the outlook for these patients. This review highlights the most promising therapeutic targets identified through new sequencing technologies, as well as through studies of apoptosis. We also present mounting evidence that the developmental signalling pathways Wnt/β-catenin, NOTCH and Hedgehog play an important role in the pathogenesis and progression of TNBC with new therapeutic approaches inhibiting these pathways in advanced preclinical studies or early clinical trials.

Keywords: BREAST CANCER; BREAST PATHOLOGY; CANCER RESEARCH.

PubMed Disclaimer

Publication types